Market Capitalization

Amid record financials and new AI breakthroughs, Cadence's CEO will address investors at a key conference to outline the firm's pivotal role in the AI era.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

With record revenue and key battery tech milestones met, Enovix is on the brink of powering smartphones, but manufacturing hurdles and cash burn remain.

A private market index tracking tech giants like SpaceX surged nearly 200% in 14 months, raising questions about a new, exclusive tier of wealth creation.

Facing financial headwinds, Mint Inc. pivots into the high-stakes world of AI, unveiling the FLOKI Minibot M1, a personalized companion for Asia.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

The legacy brand blends heritage, market strategy, and conservation with its new 8-year bourbon, inspired by 19th-century decanters and now available nationwide.

AgTech innovator Agroz Inc. faces a Nasdaq delisting warning. With 180 days to recover, its future hinges on balancing advanced tech with market realities.

Tradewinds Universal aims to consolidate the fragmented $8B adult club scene with Peppermint Hippo, but regulatory hurdles and market risks loom large.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

With overwhelming bondholder support, the media giant gains financial flexibility for shareholder returns while tightening protections for its creditors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.